Symbols

PROF

Profound Medical·NASDAQ

--(--)

PROF fundamentals

PROF Q4 2025 Earnings

Profound Medical (PROF) released its earnings on Mar 5, 2026: revenue was 5.98M (YoY +43.09%), missed estimates; EPS was -0.27 (YoY -35.00%), beat estimates.

Revenue / YoY

5.98M

+43.09%

EPS / YoY

-0.27

-35.00%

Report date

Mar 5, 2026

PROF Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue up 43% YoY to CAD 6.0 million, driven by TULSA-PRO adoption.
Clinical Success: CAPTAIN trial shows TULSA outperforms robotic surgery in 6-month quality of life metrics.
Commercial Momentum: 78 sites installed, 110 in pipeline, with new BPH module tripling TAM.
Technology Edge: TULSA's real-time MR imaging enables whole-gland treatment with focal therapy precision.
Future Outlook: Targeting 200 sites by 2026, with potential for CAD 85 million annual revenue and profitability.

Earnings

EPS

Revenue

Revenue & Expenses

PROF has released its 2025 Q4 earnings report, with revenue of 5.98M, reflecting a YoY change of 43.13%, and net profit of -8.18M, showing a YoY change of -65.25%. The Sankey diagram below clearly presents PROF's revenue sources and cost distribution.

Key Indicators

Profound Medical (PROF) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Profound Medical (PROF)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Profound Medical (PROF)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Profound Medical (PROF)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown